NIFT 2025 Exam Schedule: Stage 2 Dates Announced for Fashion Technology Entrance Exam
PorAinvest
domingo, 18 de mayo de 2025, 3:11 am ET1 min de lectura
AVIR--
The virtual investor event scheduled for May 14, 2025, at 10:00 AM ET, will feature key opinion leaders discussing the study outcomes and market opportunities. Atea's Phase 3 program includes trials in North America and globally, aiming to assess the new treatment against existing therapies. Additionally, the company has initiated a $25 million share repurchase program, reflecting a commitment to return capital to shareholders [1].
Financial results for the first quarter of 2025 indicated a net loss of $34.3 million, although this was an improvement from the previous year's loss. The company is also reviewing strategic alternatives, including potential mergers or sales, and has reduced its workforce by approximately 25% [1].
References:
[1] https://www.nasdaq.com/articles/atea-pharmaceuticals-advances-hcv-treatment-ongoing-phase-3-c-beyond-trial-and-promising
The National Testing Agency (NTA) has announced the dates for the Stage 2 examinations of the National Institute of Fashion Technology Entrance Examination (NIFTEE) 2025. The exams will take place on June 8, 2025, and interviews for postgraduate candidates will start on May 26, 2025. The exams will be conducted in Hindi and English through Computer-Based Test (CBT) or Paper-Based Test (PBT) modes, depending on the programme. Admit cards for Stage 2 will be available on the official NIFTEE 2025 portal.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) has reported significant progress in its clinical development efforts for the treatment of hepatitis C virus (HCV). The company announced ongoing enrollment in its Phase 3 C-BEYOND trial, which evaluates the combination of bemnifosbuvir and ruzasvir for HCV treatment. Positive Phase 2 results, presented at the European Association for the Study of the Liver (EASL) Congress 2025, demonstrated high efficacy and safety of the regimen [1].The virtual investor event scheduled for May 14, 2025, at 10:00 AM ET, will feature key opinion leaders discussing the study outcomes and market opportunities. Atea's Phase 3 program includes trials in North America and globally, aiming to assess the new treatment against existing therapies. Additionally, the company has initiated a $25 million share repurchase program, reflecting a commitment to return capital to shareholders [1].
Financial results for the first quarter of 2025 indicated a net loss of $34.3 million, although this was an improvement from the previous year's loss. The company is also reviewing strategic alternatives, including potential mergers or sales, and has reduced its workforce by approximately 25% [1].
References:
[1] https://www.nasdaq.com/articles/atea-pharmaceuticals-advances-hcv-treatment-ongoing-phase-3-c-beyond-trial-and-promising

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios